Literature DB >> 25535021

A race for an Ebola vaccine: promises and obstacles.

Christopher L Cooper1, Sina Bavari2.   

Abstract

While several impeding factors have limited Ebola vaccine development, the current epidemic has provided a surge which may lead to a record pace for a vaccine against Ebola. Consequently, multiple FDA trials are currently underway using two promising vaccine platforms; one has recently demonstrated durable immunity within non-human primates.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Ebola; FDA clinical trial; durable immunity; immune correlates; vaccine

Mesh：

Substances：

Year:  2014        PMID： 25535021     DOI： 10.1016/j.tim.2014.12.005

Source DB:  PubMed          Journal:  Trends Microbiol        ISSN： 0966-842X            Impact factor:   17.079


  12 in total

1.  Molecular Diagnostic Field Test for Point-of-Care Detection of Ebola Virus Directly From Blood.

Authors:  Jason W Benzine; Kerry M Brown; Krystle N Agans; Ronald Godiska; Chad E Mire; Krishne Gowda; Brandon Converse; Thomas W Geisbert; David A Mead; Yogesh Chander
Journal:  J Infect Dis       Date:  2016-09-16       Impact factor: 5.226

2.  A vaccine against Ebola: Problems and opportunities.

Authors:  Giovanni Rezza
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 3.  Backs against the wall: novel and existing strategies used during the 2014-2015 Ebola virus outbreak.

Authors:  Gary Wong; Gary P Kobinger
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

Review 4.  From bench to almost bedside: the long road to a licensed Ebola virus vaccine.

Authors:  Gary Wong; Emelissa J Mendoza; Francis A Plummer; George F Gao; Gary P Kobinger; Xiangguo Qiu
Journal:  Expert Opin Biol Ther       Date:  2017-11-17       Impact factor: 4.388

Review 5.  Moving beyond Titers.

Authors:  Benjamin D Brooks; Alexander Beland; Gabriel Aguero; Nicholas Taylor; Francina D Towne
Journal:  Vaccines (Basel)       Date:  2022-04-26

6.  T-cell-dependent mechanisms promote Ebola VLP-induced antibody responses, but are dispensable for vaccine-mediated protection.

Authors:  Christopher L Cooper; Karen A Martins; Sabrina M Stronsky; David P Langan; Jesse Steffens; Sean Van Tongeren; Sina Bavari
Journal:  Emerg Microbes Infect       Date:  2017-06-07       Impact factor: 7.163

Review 7.  A Perspective on the Development of Plant-Made Vaccines in the Fight against Ebola Virus.

Authors:  Sergio Rosales-Mendoza; Ricardo Nieto-Gómez; Carlos Angulo
Journal:  Front Immunol       Date:  2017-03-10       Impact factor: 7.561

8.  Ebola Virus Infections in Nonhuman Primates Are Temporally Influenced by Glycoprotein Poly-U Editing Site Populations in the Exposure Material.

Authors:  John C Trefry; Suzanne E Wollen; Farooq Nasar; Joshua D Shamblin; Steven J Kern; Jeremy J Bearss; Michelle A Jefferson; Taylor B Chance; Jeffery R Kugelman; Jason T Ladner; Anna N Honko; Dean J Kobs; Morgan Q S Wending; Carol L Sabourin; William D Pratt; Gustavo F Palacios; M Louise M Pitt
Journal:  Viruses       Date:  2015-12-19       Impact factor: 5.048

9.  Virus-Like Particle Vaccination Protects Nonhuman Primates from Lethal Aerosol Exposure with Marburgvirus (VLP Vaccination Protects Macaques against Aerosol Challenges).

Authors:  John M Dye; Kelly L Warfield; Jay B Wells; Robert C Unfer; Sergey Shulenin; Hong Vu; Donald K Nichols; M Javad Aman; Sina Bavari
Journal:  Viruses       Date:  2016-04-08       Impact factor: 5.048

10.  Ebola could be eradicated through voluntary vaccination.

Authors:  Andrew Brettin; Rosa Rossi-Goldthorpe; Kyle Weishaar; Igor V Erovenko
Journal:  R Soc Open Sci       Date:  2018-01-24       Impact factor: 2.963
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.